News coverage about Fulgent Genetics (NASDAQ:FLGT) has been trending positive this week, according to Accern Sentiment. The research firm identifies positive and negative press coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Fulgent Genetics earned a media sentiment score of 0.32 on Accern’s scale. Accern also assigned media coverage about the company an impact score of 46.4490287752312 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.

FLGT has been the topic of a number of research analyst reports. Zacks Investment Research upgraded Fulgent Genetics from a “hold” rating to a “buy” rating and set a $5.25 target price on the stock in a research note on Friday, August 10th. ValuEngine upgraded Fulgent Genetics from a “hold” rating to a “buy” rating in a research note on Saturday, July 14th. Credit Suisse Group cut their target price on Fulgent Genetics from $6.00 to $5.00 and set an “outperform” rating on the stock in a research note on Wednesday, May 9th. Finally, Piper Jaffray Companies restated a “hold” rating and issued a $5.10 target price on shares of Fulgent Genetics in a research note on Tuesday, August 7th. One equities research analyst has rated the stock with a hold rating and three have assigned a buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $5.12.

Shares of NASDAQ FLGT traded down $0.04 during midday trading on Friday, reaching $4.31. The company’s stock had a trading volume of 466 shares, compared to its average volume of 13,323. Fulgent Genetics has a 12-month low of $2.72 and a 12-month high of $6.06. The company has a market capitalization of $83.18 million, a PE ratio of -39.18 and a beta of 0.59.

Fulgent Genetics (NASDAQ:FLGT) last announced its earnings results on Monday, August 6th. The company reported ($0.01) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.03) by $0.02. Fulgent Genetics had a negative return on equity of 9.01% and a negative net margin of 30.93%. The firm had revenue of $5.40 million for the quarter, compared to the consensus estimate of $4.97 million. research analysts expect that Fulgent Genetics will post -0.18 earnings per share for the current fiscal year.

Fulgent Genetics Company Profile

Fulgent Genetics, Inc, together with its subsidiaries, provides genetic testing services to physicians with clinically actionable diagnostic information. Its technology platform integrates data comparison and suppression algorithms, learning software, and genetic diagnostics tools and integrated laboratory processes.

See Also: Fundamental Analysis

Insider Buying and Selling by Quarter for Fulgent Genetics (NASDAQ:FLGT)

Receive News & Ratings for Fulgent Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fulgent Genetics and related companies with's FREE daily email newsletter.